MGNX - MacroGenics (MGNX) Stock Crashes After Reporting Patient Deaths in TAMARACK Study – Hagens Berman | Benzinga

SAN FRANCISCO, May 10, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges MacroGenics, Inc. (NASDAQ:MGNX) investors who suffered substantial losses to submit your losses now.

Visit: www.hbsslaw.com/investor-fraud/mgnx
Contact the Firm Now: MGNX@hbsslaw.com
                                            844-916-0895

MacroGenics, Inc. (MGNX) Investigation:

The investigation currently focuses on the propriety of MacroGenics' statements about certain data from its Phase 2 TAMARACK study for its antibody-drug conjugate MGC018 ("vobra duo") in patients with metastatic castration-resistant prostate cancer ("mCRPC").

On Apr. 3, 2024, MacroGenics announced Phase 2 TAMARACK interim safety data as contained in its abstract submitted ...

MGNX) Stock Crashes After Reporting Patient Deaths in TAMARACK Study – Hagens Berman>Full story available on Benzinga.com